New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
Will a TIGIT refocus see the stars finally align for the partners?
The biotech surges on data with its new oncology lead, so could it have a new Padcev on its hands?
Merck adds an overall survival benefit while Bristol sinks further.
The Bristol drug's availability for adjuvant bladder cancer threw Keynote-123 out of kilter.
CG Oncology and Arrivent pull off US flotations, and both offer speculative investment cases.
A rare success for Cabometyx sees a survival benefit, but the control regimen raises questions.